Evidence map›Paper›PMID 42606794›Full record

ArticleImmunologic research2026

Clustering of rheumatoid arthritis patients: an unsupervised machine learning approach for characterizing the TNFi response.

Pedro Augusto Silva Dos Santos Rodrigues, Katarina Mattos Brandão, Lilian de Sá Garcia Landeiro, Laryssa Cardoso Calmon, Almirane Lima de Oliveira, Thamara Barbosa Miranda, João Locke Ferreira de Araújo, Rafael Valente Veiga, Camila Alexandrina Viana de Figueiredo, Pablo de Moura Santos and 1 more

Abstract read
In one paragraph

Article in Immunologic research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Pedro Augusto Silva Dos Santos RodriguesDepartment of Bioregulation, Laboratory of Immunopharmacology and Molecular Biology, Institute of Health Sciences, Federal University of Bahia, UFBA, Avenue Reitor Miguel Calmon, Canela, Salvador, BA, 40110-100, Brazil.
Katarina Mattos BrandãoDepartment of Medicine, School of Pharmacy, Federal University of Bahia, Salvador, Bahia, Brazil.
Lilian de Sá Garcia LandeiroDepartment of Bioregulation, Laboratory of Immunopharmacology and Molecular Biology, Institute of Health Sciences, Federal University of Bahia, UFBA, Avenue Reitor Miguel Calmon, Canela, Salvador, BA, 40110-100, Brazil.
Laryssa Cardoso CalmonDepartment of Bioregulation, Laboratory of Immunopharmacology and Molecular Biology, Institute of Health Sciences, Federal University of Bahia, UFBA, Avenue Reitor Miguel Calmon, Canela, Salvador, BA, 40110-100, Brazil.
Almirane Lima de OliveiraDepartment of Bioregulation, Laboratory of Immunopharmacology and Molecular Biology, Institute of Health Sciences, Federal University of Bahia, UFBA, Avenue Reitor Miguel Calmon, Canela, Salvador, BA, 40110-100, Brazil.
Thamara Barbosa MirandaCenter for Infusions and Specialized Medicines of Bahia (CIMEB), Directorate of Pharmaceutical Assistance, Health Secretary of the State of Bahia, Salvador, Bahia, Brazil.
João Locke Ferreira de AraújoDepartment of Bioregulation, Laboratory of Immunopharmacology and Molecular Biology, Institute of Health Sciences, Federal University of Bahia, UFBA, Avenue Reitor Miguel Calmon, Canela, Salvador, BA, 40110-100, Brazil.
Rafael Valente VeigaDepartment of Bioregulation, Laboratory of Immunopharmacology and Molecular Biology, Institute of Health Sciences, Federal University of Bahia, UFBA, Avenue Reitor Miguel Calmon, Canela, Salvador, BA, 40110-100, Brazil.
Camila Alexandrina Viana de FigueiredoDepartment of Bioregulation, Laboratory of Immunopharmacology and Molecular Biology, Institute of Health Sciences, Federal University of Bahia, UFBA, Avenue Reitor Miguel Calmon, Canela, Salvador, BA, 40110-100, Brazil.
Pablo de Moura SantosDepartment of Medicine, School of Pharmacy, Federal University of Bahia, Salvador, Bahia, Brazil.
Ryan Dos Santos CostaDepartment of Bioregulation, Laboratory of Immunopharmacology and Molecular Biology, Institute of Health Sciences, Federal University of Bahia, UFBA, Avenue Reitor Miguel Calmon, Canela, Salvador, BA, 40110-100, Brazil. ryansantoscosta@gmail.com.ORCID http://orcid.org/0000-0003-3075-0729

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to identifydistinct profiles of response to Tumor Necrosis Factor inhibitors (TNFi) in rheumatoid arthritis (RA) patients using unsupervised machine learning to integrate clinical, demographic, and genetic data. A cohort of 294 RA patients was analyzed using hierarchical clustering techniques. Data collected included body mass index (BMI), adherence to physical activity, prevalence of comorbidities, seropositivity, Health Assessment Questionnaire (HAQ) scores, and genetic polymorphisms in TNF pathway. Responders to TNFi demonstrated a more favorable clinical profile, with a lower BMI (25.6 vs. 27.0; p = 0.03), higher physical activity adherence (56.6% vs. 33.3%; p < 0.01), reduced prevalence of comorbidities (69.8% vs. 82.4%; p = 0.02), and improved functionality (HAQ: 0.8 vs. 1.7; p < 0.01) compared with non-responders. The C allele of rs767455 was significantly more frequent among responders (74.4% vs. 62.4%; p = 0.04). Clustering analysis identified three distinct subgroups: a better prognosis group characterized by a 73.5% response rate, minimal use of combination therapies, high adherence to physical activity, and male predominance; a poorer therapeutic response group with 82.9% therapeutic failure, intensive medication use, and low exercise adherence; and an intermediate group. TNFi response in RA is multifactorial. Integrating clinical, demographic, and genetic data enables the identification of distinct patient profiles, supporting the development of personalized treatment strategies and the advancement of precision medicine in RA management.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidTumor Necrosis Factor-alphaTumor Necrosis Factor InhibitorsUnsupervised Machine LearningAdultAgedCluster AnalysisClustering AlgorithmsFemaleHumansMaleMiddle AgedPrognosisTreatment Effect HeterogeneityTreatment OutcomeAntirheumatic AgentsTumor Necrosis Factor-alphaTumor Necrosis Factor InhibitorsCluster analysisMultivariate analysisPrecision medicineRheumatoid arthritisTumor necrosis factor inhibitors

Identifiers

PMID42606794
PMCPMC13481759

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.